Nigelle 5CH in Prevention of Influanza

• Status: Recruiting
• Trial end date: 2021-08-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will be carried out by more than 30 liberal Tunisian doctors, who will submit according to the inclusion / exclusion criteria of people who will receive (free of charge) a capsule of the Nig5 product sublingually, each day. Against a control group which will be followed with the same protocol as the first but which will not receive the product. Randomization (even days: nigella group, odd days: control group)

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hôpital Universitaire Sahloul

Criteria

Inclusion Criteria:

• patients with an age> 40 years

Exclusion Criteria:

• Being positive for COVID or having contracted it previously

• Positive for COVID between D1 and D5 of the study, meaning that there was infection before inclusion.

• Immunocompromised (HIV, other ...)

• Under chemotherapy

• On immunosuppressants

• Pregnant women